Targeted Radiotherapy, Combinations with IO and and the Impact on the Future of Treatment

Michael Groaning is the Global Medical Affairs Lead for Amgen’s Prostate Cancer portfolio which includes multiple T cell engaging bispecifics. Prior to Amgen, he lead the prostate cancer team at Endocyte in their small molecule drug conjugate program and critical in the in-licensing of Lu-177 PSMA-617. After Novartis acquired Endocyte, Mr Groaning transitioned to the role of Medical Advisor for prostate cancer until he moved on to Amgen.

Jeff Legos, PhD, is currently Executive Vice President and Global Head of Oncology and Hematology Development. Jeff is responsible for leading the development, registration, approval and life cycle management for Oncology and Hematology across 4 major platforms.  This includes a clinical pipeline of approximately 60+ targeted therapy, immuno-oncology, radioligand therapy (including Advanced Accelerated Applications drug development), cell & gene therapies and established product assets across a broad range of cancers and blood disorders. Dr Legos is also the Head of Global Precision Medicine for Novartis responsible for translational medicine and diagnostic development across all therapeutic areas, including general medicine.  He has a proven track record of successfully leading large multinational teams across all functions and stages of drug development, which has resulted in more than 30 global regulatory drug and companion diagnostic approvals, including new molecular entities, product line extensions, and premarket approvals for devices. Prior to joining Novartis in 2015, he was the Vice President and Global Medicines Development Leader in Oncology at GlaxoSmithKline (GSK) where he developed Tafinlar® (dabrafenib; BRAF inhibitor) and Mekinist® (trametinib; MEK inhibitor) as single agent and combination therapy for patients with BRAF V600 cancers, and  Promacta®/Revolade® (eltrombopag; TPO agonist) for patients with thrombocytopenia across a range of diseases.  He also previously held senior leadership positions in clinical development, translational medicine, and was the head of Oncology Strategy, where he was instrumental in the creation and growth of the GSK Oncology Business Unit.He holds a PhD in physiology from Temple University School of Medicine, an MBA in Finance from the Villanova University School of Business, and completed his post-graduate fellowship training in pharmacology and pharmaceutical medicine. He is an author of more than 40 manuscripts and numerous abstracts published in peer-reviewed journals, and has presented at major scientific and investment conferences. He is also a scientific advisor to the Melanoma Research Alliance and the recipient of several government grants, academic and corporate awards.

Matthew Silva, PhD, is the Executive Vice President of Scientific Applications at Invicro, the preeminent imaging and informatics research services and software company. As EVP of Scientific Applications, he oversees scientific and medical aspects of projects in the oncology and system disease space and participates in the strategic alignment of biomarker services across internal and collaborative groups. Dr Silva has more than 15 years of imaging and biomarker experience from pharmaceutical and contract research organizations. Prior to Invicro, he was Senior Director of Translational Biology at Vertex Pharmaceuticals and also directed imaging groups at Amgen, Millennium and Takeda Pharmaceuticals. In these roles, Dr Silva led the development of novel imaging assays and analytical methods and deployed tools to support drug discovery and development.